Ingredient producer GCI Nutrients has finalised a cannabinoid-focused strategic partnership with GVB BioPharma.
Many of the company’s customers have had concerns with the quality and legality of cannabinoid products on the market, it says, as the science behind CBD and many of the minor cannabinoids is still in the early stages. All CBD products in the USA are considered illegal by the federal government, however some 23 states including California have passed legislation regulating CBD as a dietary supplement or food ingredient.
GCI’s scientific team and GVB are focused on building the clinical evidence supporting the safe dosage levels at which humans can take cannabinoids and the clinical proof of their effectiveness on human health conditions.
GCI’s selection of GVB has been based on the company’s experience as an industrial hemp company and approach to ensuring quality at every phase in its production process at its facilities.
“GCI is in an ideal position to service our customer base. Under the terms of the agreement, GCI will represent, sell and market all of GVB’s ingredients to the dietary supplement, cosmetic and functional foods/beverage markets. GCI’s team currently has six clinical trial in progress on different herbal formulations and will be able to formulate and perform clinicals for our CBD customers,” said Drew Spiegel, COO, GVB.
Richard Merriam, CEO and founder, GCI Nutrients, said: “ The Cannabinoid challenge will not be an easy one. I believe we have the right team to support our customers expansion in product development and sales. The importance of cannabinoids in helping to solve our health problems is just beginning. There are 9 major cannabinoids in HEMP extract so there is a great deal of work to be done.”
